Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFFERIN vs PANRETIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 and older. Off-label uses include treatment of photodamage, keratosis pilaris, and actinic keratoses.
FDA-approved: Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma,Off-label: Treatment of chronic hand eczema (oral formulation, not available in US)
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
Apply 0.1% gel topically to lesions twice daily.
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites.
Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes.
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins.
>99% bound to plasma proteins, primarily albumin and lipoproteins.
Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution.
Not applicable for topical administration; systemic absorption is minimal with no established Vd.
Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible.
Systemic bioavailability after topical application is <1% of applied dose.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
No dose adjustment recommended for hepatic impairment.
Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established.
Not indicated for pediatric patients below 18 years of age.
No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin.
No specific dose adjustment; use with caution due to potential for increased skin sensitivity.
None.
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
Avoid application to cuts, abrasions, eczematous, or sunburned skin.,Avoid excessive exposure to sunlight and UV light; use sunscreen.,Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary.,Use caution in patients with eczema.,Not for oral or ophthalmic use.
Teratogenicity: Avoid use during pregnancy; effective contraception required,Photosensitivity: Avoid excessive sun exposure,Local skin reactions: erythema, edema, peeling at application site,Hyperlipidemia: Monitor lipids in prolonged use,Pancreatitis: Risk in patients with hypertriglyceridemia,Hepatotoxicity: Monitor liver function tests,Pseudotumor cerebri: Discontinue if signs of intracranial hypertension
Hypersensitivity to adapalene or any component of the formulation. Not for use in patients with known sensitivity to retinoids.
Hypersensitivity to alitretinoin or any component of the formulation,Pregnancy (topical: use only if no safer alternative; oral: absolutely contraindicated)
No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant.
No known food interactions. Avoid concurrent use of other topical products on the same area.
Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies.
PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used.
Not recommended. Excretion into human milk unknown; low systemic absorption likely but risk to infant cannot be excluded. M/P ratio not established.
No data on excretion in human milk. Retinoids are known to be excreted in animal milk. Because of potential for serious adverse reactions in nursing infants (teratogenicity, retinoid toxicity), breastfeeding is contraindicated during therapy and for at least 1 month after last dose.
Discontinue use. No dosage adjustment studies; topical application is contraindicated regardless of pharmacokinetic changes.
Contraindicated in pregnancy; no dose adjustments applicable. Ensure patient is not pregnant before initiating therapy.
Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin.
Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site.
Apply a thin layer once daily at bedtime to clean, dry skin.,Avoid excessive washing or using abrasive cleansers.,Use oil-free, non-comedogenic moisturizers and cosmetics.,Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks.,Sun protection (SPF 30+) and protective clothing are essential daily.,Minimize exposure to extreme wind or cold.,If pregnant, planning pregnancy, or breastfeeding, consult physician before use.,Keep away from eyes, mouth, nasal angles, and mucous membranes.
Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin.,Wash hands thoroughly before and after application.,Do not cover with bandages or dressings unless instructed.,Expected side effects include redness, swelling, and pain at application site.,Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFFERIN vs PANRETIN, answered by our medical review team.
DIFFERIN is a Topical Retinoid that works by Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.. PANRETIN is a Topical Retinoid that works by Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFFERIN and PANRETIN depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFFERIN is: Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.. The standard adult dose of PANRETIN is: Apply 0.1% gel topically to lesions twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIFFERIN and PANRETIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIFFERIN is classified as Category C. Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/thi. PANRETIN is classified as Category C. PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.